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The role of a-synuclein in pathogenesis of familial and idiopathic forms of Parkinson’s disease, and other
human disorders known as a-synucleinopathies, is well established. In contrast, the involvement of two
other members of the synuclein family, b-synuclein and g-synuclein, in the development and progression
of neurodegeneration is poorly studied. However, there is a growing body of evidence that a-synuclein
and b-synuclein have opposite neuropathophysiological effects. Unlike a-synuclein, overexpressed b-synu-
clein does not cause pathological changes in the nervous system of transgenic mice and even ameliorates
the pathology caused by overexpressed a-synuclein. To assess the consequences of excess expression
of the third family member, g-synuclein, on the nervous system we generated transgenic mice expressing
high levels of mouse g-synuclein under control of Thy-1 promoter. These animals develop severe age- and
transgene dose-dependent neuropathology, motor deficits and die prematurely. Histopathological changes
include aggregation of g-synuclein, accumulation of various inclusions in neuronal cell bodies and pro-
cesses, and astrogliosis. These changes are seen throughout the nervous system but are most prominent
in the spinal cord where they lead to loss of spinal motor neurons. Our data suggest that down-regulation
of small heat shock protein HSPB1 and disintegration of neurofilament network play a role in motor neurons
dysfunction and death. These findings demonstrate that g-synuclein can be involved in neuropathophysio-
logical changes and the death of susceptible neurons suggesting the necessity of further investigations of
the potential role of this synuclein in disease.
INTRODUCTION
The importance of a-synuclein in the development and pro-
gression of the human disorders known as synucleinopathies
is beyond doubt although the exact mechanism of neurodegen-
eration induced by dysfunction of this protein is the subject of
heated debate [for recent reviews see Ref. (1)]. On the other
hand, b-synuclein is believed to be a neuroprotective
factor—in several experimental in vivo systems, expression
of this protein ameliorated neuronal pathology caused by over-
expression of a-synuclein (2–7).
Despite limited information, certain known properties of
g-synuclein place it structurally and functionally in between
the other two members of the synuclein family. For instance,
g-synuclein adopts a free-state residual secondary structure
similar to a-synuclein whereas in an extended mode its struc-
ture resembles b-synuclein (8). These structural differences
correlate with different propensities of the synucleins to aggre-
gate. Aggregation of a-synuclein in vivo is believed to be a
crucial event in pathogenesis of these diseases, with intermedi-
ates (i.e. soluble oligomers) and final products (i.e. larger,
insoluble and immunohistochemically detectable aggregates)
playing different but equally important roles (1,9,10). Conver-
sely, a protective function of b-synuclein seems to correlate
with its negligible propensity to aggregate and its ability to
retard the aggregation of a-synuclein in vitro (2,11–13).
g-Synuclein is able, albeit less efficiently than a-synuclein,
to aggregate and form fibrils in vitro. However, like
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b-synuclein, it has also been shown to inhibit the aggregation
of a-synuclein (11,12). In contrast to a-synuclein, acute over-
expression of g-synuclein does not induce death of cultured
neurons but perturbs their neurofilament network by an
unknown mechanism (14,15).
While a-synuclein is the major component of Lewy bodies
and other histopathological hallmarks of synucleinopathies,
neither b-synuclein nor g-synuclein have been found in
these structures. Nonetheless, changes in their expression or
distribution (16–18) and accumulation of these proteins in
unconventional histopathological lesions within neurons and
axons (Refs 19–21 and our unpublished observations) have
been observed in several human neurodegenerative disorders
as well as certain transgenic or pharmacological animal
models of neurodegeneration (16,22–26). Therefore, it is
tempting to speculate that accumulation and aggregation of
g-synuclein might be a causative factor in the development
of certain, yet to be identified, types of neurological disorders.
To test whether increased and/or ectopic expression of
mouse g-synuclein could trigger neurohistopathological
changes and phenotypes typical for synucleinopathies, we pro-
duced transgenic mice with pan-neuronal overexpression of
this protein. Animals expressing high levels of g-synuclein
develop severe and fatal neurological disease associated with
aggregation of the overexpressed protein and its deposition
in cytoplasmic and axonal lesions.
RESULTS
Production of transgenic animals and analysis of transgene
expression
Transgenic mice expressing elevated levels of mouse wild-
type g-synuclein were generated using the Thy-1 neuron-
specific expression cassette (Fig. 1A) that we and others
have used previously for generating lines expressing high
levels of either a-synuclein (27–30) or b-synuclein (5).
Mice from one line, Thy1mgSN, expressed high levels of
mouse g-synuclein throughout the nervous system and devel-
oped an age-dependent neurological phenotype. Mice of a
second line with lower levels of the transgene expression did
not develop a noticeable phenotype and were excluded from
this study.
Transgenic mice were produced on a pure genetic back-
ground and the colony was maintained by backcrossing hemi-
zygous Thy1mgSN mice with C57Bl6 mice. These
hemizygous animals were indistinguishable from their wild-
type littermates during the first year of their life. Later most
of these mice developed a clasping reflex, abnormal posture
and gait, as well as other signs of motor dysfunction (see
below). In an attempt to augment the pathology we bred
Thy1mgSN mice to homozygosity. This resulted in an
approximate doubling of the transgene expression levels,
which in dorsal root ganglia (DRG) of 12-month-old mice
reached the level that was approximately seven times higher
than the level of endogenous g-synuclein mRNA in these
ganglia (Fig. 1B). Offspring from intercrosses of hemizygous
parents showed a normal Mendelian distribution of genotypes.
Homozygous animals appeared normal during the first few
months of life despite a very high level of g-synuclein
mRNA expression throughout their nervous system. For
instance, in the spinal cord of young adult homozygous trans-
genic animals, the level of this mRNA was approximately 16
times higher than in the trigeminal ganglion of wild-type mice
that was used for reference due to the high endogenous level
of g-synuclein mRNA expression and homogeneity of cell
population in this structure (Fig. 1B, top panel). In the
spinal cord of wild-type animals, only motor neurons
express g-synuclein (31), but in Thy1mgSN mice, motorneur-
ons and additional types of spinal neurons expressed
g-synuclein, which explains, in part, the robust increase of
both g-synuclein mRNA (Fig. 1B, bottom panel) and protein
(Fig. 1C and D) levels. The same applied to other regions
(Fig. 1D and data not shown) where endogeneous g-synuclein
expression is restricted to certain neuronal populations (32)
but the transgene is expressed in the majority of neurons. Sub-
stantial accumulation of g-synuclein did not affect the levels
of expression of the other two members of synuclein family
(Fig. 1D).
Overexpression of g-synuclein is associated with a severe
neurological phenotype and early lethality of transgenic
mice
The health of homozygous animals started to deteriorate sub-
stantially from the age of 6–9 months. The first signs of path-
ology were similar to those observed in the older hemizygous
mice, including clasping reflex, hunchback posture and abnor-
mal gait (Fig. 2A–C and Supplementary Material movie). In
contrast to hemizygous animals, clinical signs of pathology
in homozygous animals progressed rapidly with all animals
developing pareses of their limbs by the age of 9–16
months followed by paralyses and loss of the righting reflex
(Fig. 2D). At this stage, the animals were sacrificed to
prevent further suffering. Typically, the paraparesis of the
forelimbs became obvious earlier than that of the hindlimbs.
Lifespan of homozygous transgenic mice was also limited;
not a single mouse survived beyond the age of 16 months in
two independent cohorts (total 74 mice) housed in two
animal facilities (Fig. 2E).
The onset and progression of motor dysfunction was quan-
tified using several different tests. Balance and coordination
were already significantly impeded in homozygous
Thy1mgSN mice younger than 6 months before they displayed
obvious clinical signs of pathology (Fig. 3 and Supplementary
Material Tables S1 and S2). Their ability to turn on an 11 mm
diameter beam and their performance on a constant speed
rotarod were both compromised by the age of 4 months
(Fig. 3A and Supplementary Material Table S1). Using the
accelerating rotarod test, it was possible to demonstrate
motor impairments as early as at 2 months of age. At this
time point the homozygous Thy1mgSN mice were indistin-
guishable from wild-type mice by any other criteria examined
(Fig. 3B). Hemizygous Thy1mgSN mice developed a similar
motor dysfunction but with a much greater latency and
slower progression. This is exemplified by their performance
on the rotarod that only declined significantly after the age
of 18 months (Fig. 3). In the footprint test, the length of
stride of hemizygous 18-month-old animals was significantly
shorter than that of their wild-type littermates, while
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homozygous mice already showed this impairment at the age
of 6 months (Supplementary Material Fig. S1 and data not
shown). The horizontal beam test was most sensitive for
detecting early signs of motor deficit in hemizigous
Thy1mgSN animals; their ability to perform both parts of
the task was already obviously compromised at the age of
12 months (Supplementary Material Tables 1 and 2).
In summary, pan-neuronal overexpression of mouse
g-synuclein in transgenic mice was associated with a progressive
age- and gene dose-dependent motor phenotype that recapitulates
phenotypes described earlier for several lines expressing human
a-synuclein under control of the same Thy-1 promoter or other
pan-neuronal promoters (27,30,33–39).
Aggregation and fibrillation of g-synuclein in the nervous
system of transgenic mice
It was feasible to suggest that pathological changes in the
nervous system of Thy1mgSN transgenic mice would also
be similar to the changes observed in the nervous system of
Figure 1. Expression of g-synuclein in wild-type and transgenic mice. (A) A map of DNA fragment used for producing transgenic animals. A mouse g-synuclein
cDNA fragment was inserted between exons II and IV of the mouse Thy-1 gene. (B) Expression of g-synuclein mRNA in neuronal tissues of wild-type and
transgenic animals measured by quantitative real-time RT–PCR. Bar charts show the fold g-synuclein mRNA level increase (mean+SEM) in the spinal
cord of homozygous and heterozygous 8-week-old Thy1mgSN mice compared with the level in the trigeminal ganglion of newborn wild-type mice (top
chart) and in the DRG and spinal cord of homozygous 12-month-old Thy1mgSN mice compared with the level in the DRG of 12-month-old wild-type mice
(bottom chart). (C) Western blot analysis of g-synuclein in the spinal cord of 1-year-old wild-type and homozygous Thy1mgSN animals. The top panel
shows a normalization western blot simultaneously probed with antibodies against GAPDH and g-synuclein. The same undiluted wild-type samples and
1:1000, 1:500 or 1:250 diluted transgenic samples were analysed on a western blot shown in the bottom panel. (D) Western blot analysis of three synucleins
in the spinal cord and brain regions of 1-year-old wild-type and Thy1mgSN transgenic (hemi- and homozygous) animals. More g-synuclein accumulates in
neuronal tissues of homozygous than hemizygous mice but a ladder of multimeric g-synuclein-positive bands is not observed even on overexposed western
blots (top panels).
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Figure 2. Transgenic animals develop pathology that leads to premature death. Typical appearance of Thy1mgSN transgenic mice at the initial stage of path-
ology development with clasping of all limbs when hanging by the tail (A) and a hunchback posture (B). Examples of severe gait abnormality in 9- and
12-month-old homozygous g-synuclein transgenic mice detected by the footprint test. Forefeet prints are blue and hindfeet prints are red (C). At the advanced
stage of pathology, the righting reflex is substantially impaired (D). Kaplan–Meier plot of wild-type (squares, n ¼ 49), hemizygous Thy1mgSN (triangles,
n ¼ 87) and homozygous Thy1mgSN (circles, n ¼ 74) mice survival over the 26 months period (E).
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a-synuclein transgenic animals and might be accompanied by
aggregation of g-synuclein in neurons and their processes.
Therefore, we looked for signs of g-synuclein aggregation
throughout the nervous system of homozygous Thy1mgSN
mice that developed obvious pathology.
Immunohistochemical analysis of Thy1mgSN brain and
spinal cord sections stained with highly specific SK23 anti-
body (31) revealed increased production of g-synuclein in
many neurons expressing endogenous g-synuclein as well as
ectopic production in other neurons normally devoid of this
protein. In contrast to the predominantly neuritic localization
of endogenous g-synuclein in the brain of adult wild-type
mice (32), overproduced protein also accumulated in the neur-
onal cell bodies (Supplementary Material Fig. S2). Although
immunostaining in the majority of transgenic mouse brain
neurons was diffusely distributed throughout the cytoplasm,
in subsets of neurons, we detected g-synuclein-positive
cytoplasmic inclusions which, in some cases, were clearly
eosinophilic and also showed some remarkable resemblance
to the a-synuclein-positive structures seen in Lewy body dis-
eases (Fig. 4A and Supplementary Material Fig. S2D and E).
However, much more typical was the presence of
g-synuclein-positive spheroids and dystrophic neurites
(Fig. 4A and Supplementary Material Fig. 2D and E) that
were not seen in the nervous system of wild-type littermates
(Fig. 4A and data not shown).
These abnormal structures were observed throughout the
nervous system but were most abundant in the spinal cord
(Fig. 4A), which is consistent with the observed clinical
pattern of pathology. Therefore, the spinal cord was used to
determine whether aggregated and fibrillated forms of
g-synuclein were present in neuronal tissues of animals over-
expressing this protein. Sequential fractionation of the spinal
cord tissues demonstrated that, in contrast to endogenous
Figure 3. Rotarod performance of g-synuclein transgenic mice. Groups of mice of different ages and genotypes were tested on Ugo Basile rotarod using constant
speed (A) or accelerating (B) modes as described in Material and methods. Line graphs show mean+SEM of latency to fall for wild-type (diamonds), hemi-
zygous Thy1mgSN (squares) and homozygous (triangles) Thy1mgSN mice at different age. Statistically significant difference (P, 0.01, Student’s t-test) in
performance between transgenic and wild type groups at particular age is denoted by asterisks.
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g-synuclein, which was completely soluble in salt/non-ionic
detergent buffers, a substantial fraction of g-synuclein in the
spinal cord of Thy1mgSN mice remained insoluble after
extraction with these solutions but could be partially solubil-
ized in the ionic detergent-containing buffers (Fig. 4B) or in
formic acid (data not shown). Immuno-electron microscopy
of sarcosyl-insoluble material revealed the presence of fila-
ments decorated with antibody against g-synuclein (Fig. 4C).
These results demonstrate that increased expression of
g-synuclein in mouse neurons can cause aggregation and
fibrillation of this protein followed by formation of large intra-
cellular inclusions.
Histopathology in the spinal cord of transgenic mice
Amyloid-like inclusions were detected by Congo Red
(Fig. 5B–D) or thioflavine S (data not shown) staining of
spinal cord or brain tissue of hemi- and homozygous mice,
even at a stage when clinical signs of pathology were mild
(only clasping reflex). The number of the Congo Red-positive
inclusions substantially increased as disease progressed
(Fig. 5E).
Neuronal degeneration is commonly associated with the
activation of microglia and astroglia in affected regions of
the nervous system. A large number of GFAP-positive cells
with morphology typical for activated astrocytes were found
in the spinal cord gray matter of severely affected homozygous
Thy1mgSN mice (Fig. 6A). The level of GFAP was also sub-
stantially increased in the spinal cord tissue of homozygous
and, to a lesser extent, age-matched hemizygous animals
without obvious signs of pathology (Fig. 6B) but not in the
spinal cord of young homozygous mice. However, using anti-
bodies against two different markers, Iba1 and CD11b, we
failed to detect clear signs of microglia activation (data not
shown).
Another common feature of synucleinopathies is the pre-
sence of ubiquitin-positive inclusions in affected regions of
the nervous system. In the spinal cord of g-synuclein
Figure 4. g-Synuclein-positive aggregates and fibrils in the spinal cord of 12-month-old transgenic mice detected by anti-mouse g-synuclein SK23 antibody. (A)
Immunostained transverse sections through the spinal cord of wild-type and homozygous g-synuclein transgenic mice. Higher magnification images of the
ventral horn region are shown on lower panels, scale bars ¼ 50 mm. A g-synuclein-positive cytoplasmic inclusion (further magnified in the left inset) is indicated
by the small arrowheads, spheroids by large arrowheads, dystrophic and ballooned neurites by small and large arrows, correspondingly. The right insert shows a
hematoxylin and eosin-stained spinal cord motor neuron with an eosinophilic cytoplasmic inclusion, scale bar ¼ 20 mm. (B) Western blot analysis of g-synuclein
in high salt (HS), HS/Triton X-100 (HS/T), RIPA- and SDS-soluble fractions of the spinal cord of wild-type, hemizygous and homozygous mice. (C)
Immuno-electron microscopy detection of g-synuclein fibrils in a sarcosyl-insoluble fraction of the homozygous Thy1mgSN mouse spinal cord.
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Figure 5. Amyloid deposits in the spinal cord of g-synuclein transgenic mice. Representative images of Congo Red-stained spinal cord sections of 12-month-old
wild-type mouse (A), hemizygous Thy1mgSN mouse (B), homozygous Thy1mgSN mouse at the advance stage of pathology (C) and homozygous Thy1mgSN
mouse with mild signs of pathology (D) are shown. Scale bar ¼ 200 mm for all main panels and 25 mm for all insets. The bar chart shows mean+SEM. of the
number of deposits per randomly selected 0.1 mm2 area of the spinal cord gray matter. Sections for counting [104 for (A), 121 for (B), 93 for (C) and 72 for (D)]
were randomly selected throughout the length of cervical, thoracic and lumbar parts of the spinal cord of at least four animals per group. One-way ANOVA with
post hoc Fisher’s protected t-test demonstrated significant (P , 0.01) difference between all four experimental groups.
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transgenic animals, we detected multiple abnormal ubiquitin-
positive structures (Fig. 6C). However, double immunofluor-
escence revealed only partial overlap between g-synuclein-
positive and ubiquitin-positive profiles (Fig. 6D). Furthermore,
western blot analysis did not reveal g-synuclein-laddered
staining patterns reminiscent of different degrees of ubiquiti-
nation (for example, see Fig. 1D). Therefore, most of the
aggregated g-synuclein in the spinal cord of Thy1mgSN
mice are probably not ubiquitinated, but ubiquitin and/or
some ubiquitinated proteins are present in the inclusions that
appear in the nervous system of these mice.
Loss of motor neurons in the spinal cord of transgenic mice
The emergence of pathological inclusions and astrogliosis in
Thy1mgSN mice coincides with the loss of motor neurons
in the spinal cord (Fig. 7). Twelve-month-old homozygous
animals with severe motor impairments possessed less than
40% of their wild-type littermates spinal motor neuron comp-
lement (Fig. 7E). Age-matched hemizygous and homozygous
mice that developed milder motor impairment (clasping
reflex and pareses of one limb but normal righting, for
example see Supplementary Material movie) also displayed
motor neuron loss but to a far lesser extent (Fig. 7E).
Similar results were obtained in cervical, thoracic and
lumbar parts of the spinal cord (data not shown).
Neurodegeneration in the spinal cord of motor neuron disease
patients is often associated with dysfunction of intracellular
systems that are responsible for correct folding of protein mol-
ecules. Survival of spinal motor neurons seems to rely on mol-
ecular chaperons including small heat shock proteins (40–44).
Therefore, we used western blot analysis to examine the levels
of large (HSP70) and small (HSPB1 also known as HSP27 or, in
mouse, HSP25) heat shock proteins in the spinal cords of
Thy1mgSN mice. While the levels of HSP70 were similar in
age-matched transgenic and wild-type animals, the levels of
HSPB1 were dramatically increased in all ageing transgenic
animals and particularly in those that displayed severe motor
impairment (Supplementary Material Fig. S3). However, this
increase was due to high levels of HSPB1 in activated astrocytes
(Fig. 7F and Supplementary Material Fig. S4), whereas in spinal
motor neurons of transgenic animals the level of this protein
was substantially lower than in spinal motor neurons of wild-
type mice (Fig. 7F).
Figure 6. Astrogliosis and ubiquitin-positive inclusions in the spinal cord of
g-synuclein transgenic mice. (A) Transverse sections through the spinal
cord of wild-type and severely affected homozygous Thy1mgSN mice immu-
nostained for GFAP. Higher magnification images are shown on lower panels,
scale bars ¼ 20 mm. (B) Western blot of total protein extracts from
12-month-old wild-type, hemizygous and homozygous transgenic mice
probed with antibodies against g-synuclein, GFAP and GAPDH as a loading
control. (C) Transverse sections through the spinal cord of severely affected
homozygous Thy1mgSN mouse immunostained for ubiquitin. Boxed areas
of gray and white matter are shown at higher magnification on the right top
and right bottom panels, correspondingly. (D) Double immunofluorescent
staining of severely affected Thy1mgSN mouse spinal cord section with anti-
bodies against ubiquitin (green) and g-synuclein (red). Examples of dystrophic
neuritis and spheroids positive only for g-synuclein are marked with large
arrows, positive only for ubiquitin—with small arrows and positive for both
proteins—with arrowheads. Scale bar ¼ 50 mm.
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Neurofilaments in the spinal cord and peripheral nerves of
transgenic mice
HSPB1 is thought to be involved in regulation of the neurofila-
ment network assembly in normal motor neurons and its mutant
variants affect neurofilament-L (NF-L) aggregation in certain
forms of Charcot–Marie–Tooth disease (45–47). An acute
overexpression of g-synuclein in cultured neurons also perturbs
their neurofilament network integrity (15). Therefore, we ana-
lysed neurofilaments in the spinal motor neurons of transgenic
mice chronically overexpressing g-synuclein. Western blot
analysis of the non-ionic detergent soluble fraction of
Thy1mgSN mouse spinal cord revealed not only monomeric
full-length 67 kDa NF-L but also distinct lower molecular
weight NF-L species (Fig. 8A), possibly products of specific
and restricted breakdown that were not seen in similar fractions
of wild-type mouse spinal cord tissue. Decrease of these trun-
cated species in the spinal cord of severely affected animals
probably reflects loss of neurons that produced them. Overex-
pressed g-synuclein co-immunoprecipitated with soluble
NF-L, although substantially less amount of this protein was
pulled-down from spinal cord lysates of animals at the
advance stages of pathology than from similar lysates of
less-affected animals (Fig. 8B).
Immunostaining of histological sections with antibody
against NF-L did not reveal accumulation of this protein in
g-synuclein-positive or any other pathological profiles in the
spinal cord of transgenic animals (Fig. 8C). However, substan-
tial reduction in staining intensity in the spinal cord of
Thy1mgSN mice when compared with wild-type tissue was
observed (Fig. 8C). This reduction was mainly confined to
neuronal processes and not the motor neuron cell bodies
(Fig. 8D, upper panels). It was even more obvious in longi-
tudinal sections through peripheral nerves of Thy1mgSN
mice where only thin and wavy neurofilament-positive
strings were found (Fig. 8D, lower panels). In addition,
severe axonal pathology in the form of multiple nerve fibre
swellings was revealed in the sciatic nerve of ageing homozy-
gous Thy1mgSN mice (Fig. 8D, lower panels). Similar
changes were also observed in tissue sections stained with
antibodies against two other neurofilament proteins (data not
shown). These results suggest that overexpression of
g-synuclein in transgenic mouse neurons seriously compro-
mises the organization of neurofilaments in neuronal processes
and, consequently, the architecture and function of axons.
DISCUSSION
Previous studies of transgenic mice overexpressing members
of the synuclein family have revealed the contrasting effects
of a-synuclein and b-synuclein on the development of patho-
logical changes in the nervous system of these animals. High
levels of a-synuclein in neurons cause a prominent neurologi-
cal phenotype although the manifestations are variable and
dependent on the a-synuclein isoform and type of promoter
used for production of that particular transgenic line (reviewed
in Refs. 48–50). In contrast, overexpression of b-synuclein
does not have a harmful effect on animal health and even
counteracts a-synuclein neurotoxicity (5–7). These results
echo differences in aggregation propensity, cytotoxicity and
certain structural features of these two proteins. As discussed
in the Introduction, g-synuclein has molecular features shared
with both a- and b-synuclein. Therefore, it was not possible to
predict the consequences of g-synuclein overexpression in the
nervous system of transgenic animals. Revealing the effects of
aberrant expression of g-synuclein in vivo is important not
only for better understanding of relationships between struc-
ture and function within synuclein family. This information
would also be valuable for development of new therapeutic
approaches to combat synucleinopathies.
No disease-associated mutations of g-synuclein gene or
obvious cases of idiopathic human g-synucleinopathies have
been reported so far and the amino acid similarity between
human and mouse proteins is high. Taking these facts into
consideration, we decided to create a simple homologous
model in which mouse g-synuclein was overexpressed in the
majority of neurons of the mouse nervous system. To
achieve this we produced Thy1mgSN transgenic mice, expres-
sing high levels of mouse g-synuclein under control of the
Thy-1 promoter cassette that has previously been used for pro-
ducing several a-synuclein (27–30) and a b-synuclein (5)
transgenic animal lines. In relatively homogeneous popu-
lations of neurons that normally express g-synuclein, for
example the DRG, there was approximately a 7-fold increase
of g-synuclein mRNA expression in homozygous Thy1mgSN
transgenic mice compared with wild-type mice.
In homozygous transgenic mice, g-synuclein aggregates and
accumulates in abnormal structures within neuronal cell
bodies and neurites. These g-synuclein-positive structures
resemble pathological hallmarks of synucleinopathies,
namely dystrophic, beaded and ballooned neurites, spheroids,
and even, occasionally, Lewy bodies. Like aggregated
a-synuclein, aggregated g-synuclein could not be extracted
from transgenic mouse neural tissues using non-ionic deter-
gents, but is partially soluble in sarcosyl-containing buffers.
At least a fraction of aggregated g-synuclein forms linear
fibrils that are structurally similar, although not identical to
products of a-synuclein fibrillation in vivo or in vitro.
Multimeric forms of a-synuclein are commonly detected on
western blots of SDS-soluble proteins extracted from neural
tissues of patients suffered from synucleinopathies or
a-synuclein transgenic mice (35,37,38,51–55). These higher
molecular weight bands represent either SDS-resistant
a-synuclein oligomers or ubiquinated forms of the protein.
We did not observe similar concatomeric g-synuclein
species in extracts of g-synuclein transgenic mouse brain or
spinal cord. This might suggest that the oligomeric intermedi-
ates of g-synuclein aggregates are either not accumulating to a
significant level in neurons of transgenic mice or that they are
readily solubilized to monomeric g-synuclein in
SDS-containing buffers. It also suggests that even aggregated
g-synuclein is rarely ubiquitinated, which is consistent with
our observation that g-synuclein-positive inclusions in the
spinal cord of transgenic mice often do not co-localize with
ubiquitin-positive structures. The most probable explanation
of our results is that ubiqutination is neither required for nor
accompanies g-synuclein aggregation but ubiquitin or certain
ubiquitinated proteins may accumulate in pathological
inclusions. Moreover, pathological changes in the nervous
system of transgenic mice may trigger secondary events,
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including aggregation of ubiquitinated proteins and formation
of ubiquitin-positive/g-synuclein-negative inclusions that we
have observed on double-immunostained sections of the
spinal cord. Similar partial overlap of a-synuclein and ubiqui-
tin staining patterns has been found previously in the nervous
systems of patients with synucleinopathies and a-synuclein
transgenic mice, though ubiquinated a-synuclein is relatively
abundant in these tissues (56).
The common features of a-synuclein pathology in human
patients and transgenic mice are abundant amyloid deposits
and activated glial cells in affected areas of the nervous
system. In the brain and spinal cord of g-synuclein transgenic
mice, we also observed multiple amyloid (Congo Red- and
Thioflavin S-positive) deposits and prominent astrogliosis,
but no activated microglia was detected.
Although all pathological changes described above were
observed throughout the central nervous system of
Thy1mgSN mice, the spinal cord was noticeably more affected
than any other region, which is similar to the reports on trans-
genic mice expressing a-synuclein under control of the same
Thy-1 promoter (Refs 27,29,57 and our unpublished obser-
vations). This probably reflects the higher sensitivity of spinal
cord neurons, particularly motor neurons, to high levels of
both members of the synuclein family.
The ultimate consequence of g-synuclein overexpression in
transgenic mice is death of motor neurons. Correspondingly,
these mice display clinical signs typical for motor neuron
disease, namely a gradual development of motor deficit fol-
lowed by pareses and paralyses, which are most obvious in
limb muscles. At this terminal stage of the disease,
g-synuclein transgenic animals lose more than 60% of
ventral horn motor neurons.
The development of neurological phenotype and histopatho-
logical findings in our mice suggests that pan-neuronal overex-
pression of g-synuclein in mice could trigger pathological
changes typical for synucleinopathies and most apparent in
the spinal cord. The burden of pathology increases with age,
which leads to a gradual loss of spinal motor neurons and the
development of motor dysfunction. The onset, penetrance and
degree of neuropathology directly correlate with the level of
transgene expression because the hemizygous animals, which
express 50% less transgenic g-synuclein than the homozygous
animals, develop clinical signs later in their life and show less
pronounced histopathological changes in their nervous system.
One intriguing question is which molecular and cellular pro-
cesses previously linked to the development of neurodegenera-
tion become compromised in the nervous system of g-synuclein
transgenic mice? Recent studies on the mechanisms of neurode-
generation in humans and in various model organisms demon-
strate that simultaneous dysfunction of several systems
safeguarding cell homeostasis is required for the development
of a full-scale pathology. However, some types of neurons are
particularly sensitive to dysfunction in certain intracellular
systems. Pathogenesis of motor neuron diseases often involves
disruption of neurofilament networks in motor neuron cell
bodies and axons (reviewed in Refs 58–61). While this disrup-
tion could be triggered by various mechanisms, in the majority
of cases changes in the structure or metabolism of NF-L, a
subunit required for assembly of neurofilaments in vivo, play
a crucial role (45,62–67). We have demonstrated that chronic
overexpression of g-synuclein in mouse motor neurons leads
to substantial depletion of neurofilaments in neuronal processes.
This might be an essential event in pathogenesis of axonal path-
ology in peripheral nerves and consequent development of
motor dysfunction in g-synuclein transgenic mice. This result
is consistent with our previous findings that acute overexpres-
sion of g-synuclein affects neurofilament network integrity in
cultured neurons, particularly their axons (15). The exact mech-
anism of the disruptive effect of overexpressed g-synuclein on
neurofilaments remains to be elucidated but its ability to
interact with soluble NF-L and accumulation of abnormal
NF-L-reactive soluble polypeptides in the spinal cord of
Thy1mgSN mice suggest that normal homeostasis, including
transport of NF-L to axons, might be at least partially prevented
by trapping this protein in complexes with g-synuclein and/or
abnormal degradation. Disruption of axonal neurofilaments
follows the reduction of NF-L axonal traffic. Moreover, trun-
cated NF-L species could also affect neurofilament assembly
and/or stability.
Some histopathological changes observed in Thy1mgSN
mice, including astrocytosis and loss of motor neurons and
their axons, are similar to those observed in aged NF-L null
mutant mice (67). However in g-synuclein transgenic mice,
the pathological phenotype develops much earlier and is sub-
stantially more severe. This suggests that, in addition to the dis-
rupted neurofilament network, other intracellular systems are
also compromised in the motor neurons of these animals. Mol-
ecular chaperons belonging to the family of heat shock proteins
play an important protective role in motor neurons. These cells
seem to be particularly vulnerable to dysfunction of the small
heat shock protein HSPB1 (40–44) and mutations of the
HSPB1 gene cause certain types of motor neuron diseases
(45–47). In motor neurons of g-synuclein transgenic mice,
the level of HSP25, a mouse ortholog of HSPB1, is substantially
reduced, potentially compromising the survival of these cells.
Although some a-synuclein transgenic mice develop similar
clinical signs of the spinal cord pathology to g-synuclein trans-
genic mice, neither down-regulation of HSPB1 nor changes of
the neurofilament network in their motor neurons has been
reported. Taken together with other data, this suggests that
diverse but partially overlapping mechanisms underlie devel-
opment of pathology in these two mouse models.
Figure 7. Loss of motor neurons and changes of HSPB1 expression in the spinal cord of g-synuclein transgenic mice. Representative images of cresyl fast violet-
stained spinal cord sections of 12-month-old wild-type mouse (A), hemizygous Thy1mgSN mouse (B), homozygous Thy1mgSN mouse at the advance stage of
pathology (C) and homozygous Thy1mgSN mouse with mild pathology (D) are shown. (E) The bar chart shows mean+SEM. of the number of motor neurons
per section expressed as percent of the average number of motor neurons per section of the wild-type mouse spinal cord. Sections for counting [160 for (A), 332
for (B), 215 for (C) and 139 for (D)] were randomly selected throughout the length of cervical, thoracic and lumbar parts of the spinal cord of at least four
animals per group. One-way ANOVA with post hoc Fisher’s protected t-test demonstrated significant (P,0.01) difference between all four experimental
groups. (F) Double immunofluorescent staining of spinal cord sections from a wild-type mouse and severely affected homozygous Thy1mgSN mouse with anti-
bodies against neurofilament-L (green) and HSPB1 (red). Scale bar ¼ 20 mm.
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Figure 8. Neurofilaments in the spinal cord and peripheral nerve of g-synuclein transgenic animals. (A) Western blot analysis of soluble neurofilament-L in the
cytosolic (10 000g supernatant) fraction of the spinal cord of 12-month-old wild-type mice, hemizygous Thy1mgSN mice, homozygous Thy1mgSN mice with
mild clinical signs of pathology and homozygous Thy1mgSN mice at the advance stage of pathology. (B) Co-immunoprecipitation of g-synuclein and soluble
neurofilament-L from the same cytosolic fractions. (C) Double immunofluorescent staining of severely affected Thy1mgSN mouse spinal cord section with anti-
bodies against neurofilament-L (green) and g-synuclein (red) shows the absence of NF-L accumulation in g-synuclein-positive pathological profiles. (D) Sub-
stantial reduction of neurofilament-L staining in the ventral horns of the spinal cord (upper panels) and sciatic nerve (lower panels) of 12-month-old homozygous
Thy1mgSN mice at the advance stage of pathology compared with their wild-type littermates. Scale bars ¼ 20 mm for (C) and 50 mm for (D).
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In conclusion, we have demonstrated that transgenic mice
expressing high levels of g-synuclein in their neurons
develop a severe neurodegenerative pathology. It is feasible
that, under certain conditions, g-synuclein could be involved
in the development of pathological changes in human
neurons. Further studies on the role of this synuclein in
normal and degenerating neurons might therefore provide
additional insight into the mechanisms leading to human neu-
rodegenerative diseases.
MATERIALS AND METHODS
Generation of transgenic animals
A fragment of mouse g-synuclein cDNA including 34 bp of
50-UTR and 64 bp of 30-UTR was PCR amplified using
pD53 plasmid DNA (31) as a template and oligonucleotides
with XhoI linkers (mgSN XhoI-F: 50-CTACTGTCCGCTCG
AGCTTGCAGCAGCCAGGTTC-30 and mgSN XhoI-R:
50-CTACTGTCCGCTCGAGGCCTTCTAGTCTTCTCCA-
C-30) to facilitate subsequent cloning into XhoI site of Thy-1
promoter plasmid 323-pTSC21k (27). The fragment for micro-
injecting mouse oocytes was isolated by digestion of the
resulting plasmid DNA with NotI. Transgenic founders were
produced on C57Bl6 genetic background. Animals positive
for transgene expression were crossed with C57Bl6 wild-type
mice. Transgenic and wild-type animals were identified by
PCR analysis of DNA from ear biopsies. The presence of a
1 kb product in the amplification reaction with primers
HP45 ThyI f2 (50-ACACCCCTAAAGCATACAGTCAGAC
C-30) and HP84 m gSN (50-GGCCTTCTAGTCTTCTCCA
CTCTTG-30) indicated the presence of transgene in the
mouse genome. Experimental cohorts were formed from
litters produced by intercrossing hemizygous animals. Hemi-
and homozygous animals were discriminated by quantitative
real-time PCR analysis of DNA from ear biopsies and verified
by analytical backcrossing followed by offspring genotyping.
All animal work was carried in accordance with the United
Kingdom Animals (Scientific Procedures) Act (1986).
Motor performance tests
Rotarod tests. Animals were tested on Ugo Basile 7650
rotarod at 2, 4, 6, 9, 12, 18 and 24 months of age. A constant
(24 rpm) speed test was carried out for 4 min and accelerating
(4–40 rpm) speed test for 5 min as described previously (68).
Each mouse was tested three times in each mode with at least
30 min rest between trials. The mean of latency to fall for
these three trials was included in final statistics. Eleven wild
type, 12 hemizygous and 13 homozygous mice were tested
at 2 months: 28, 27 and 21, at 4 months; 35, 40 and 23, at 6
months; 34, 36 and 23, at 9 months; 25, 26 and 14, at 12
months of age. No homozygous animals survived beyond 16
months therefore at this age and at 24 months only wild-type
(12 and 15, respectively) and hemizygous (21 and 15, respect-
ively) animals were tested.
Horizontal beam test. Animal coordination was tested on an
11 mm diameter and 50 cm long horizontal wooden rod at 4,
6, 9 and 12 months of age. A mouse was placed at the free
hanging end of the rod facing its end. The ability to turn
1808 and to reach an escape black box at the other end of
the rod was recorded.
Footprint test. Animals were trained to run along a narrow
passage lined with a strip of white paper before carrying out
the test run. For this run, mouse forefeet were coated with blue
ink and hindfeet with red ink. Different parameters of the stride
were measured and analysed as described previously (69).
RNA expression analysis
Total RNA from various regions of the nervous system was
extracted using RNAEasyþ kit as recommended by the man-
ufacturer (Qiagen). First-strand cDNA was synthesized using
random primers (Promega) and SuperScriptIII reverse tran-
scriptase (Invitrogen). Quantitative PCR was performed on
StepOne Real-Time PCR System (Applied Biosystems) with
DyNAmo HS SYBR Green supermix (Finnzymes) and ROX
as a passive reference dye. Reactions were carried out in one-
piece thin-wall 48-well PCR plates (Bioplastics). GAPDH
mRNA was used as a normalization standard. Primers
50-CCATGGACGTCTTCAAGAAAGG-30 and 50-CGTTCTC
CTTGGTTTTGGTG-30 were used for amplification of
g-synuclein cDNA, and primers 50-CACTGAGCATCTCC
CTCACA-30 and 50-GTGGGTGCAGCGAACTTTAT-30 for
amplification of GAPDH mRNA. After hot start (10 min at
958C), 40 cycles of 15 s at 958C and 60 s at 608C were
carried out followed by melting curve determination with
0.38C steps. Fold change was determined by 22DDCT method
as described previously (70) using StepOne v2.0 software.
Protein extraction
Total tissue proteins were extracted by homogenization of
tissues directly in SDS–PAGE loading buffer followed by
incubation for 10 min at 1008C. For analysis of cytosolic pro-
teins, tissues were homogenized in 50 mM Tris–HCl, pH 7.5;
150 mM NaCl; 1% Triton X-100 buffer with protease inhibi-
tors (Complete Mini from Roche) and cytosolic fraction was
obtained by centrifugation for 10 min at 10 000g.
Sequential protein extraction
A previously described protocol (37) was used with minor
modifications. Briefly, neuronal tissues were homogenized in
5 volumes of high salt (HS) buffer (50 mM Tris–HCl, pH
7.5; 750 mM NaCl; 5 mM EDTA) with protease inhibitors
(Complete Mini from Roche) and centrifuged at 100 000g
for 20 min at 48C. Pellets were washed in the same buffer
and then re-extracted in HS buffer containing 1% Triton
X-100 (HS/T-soluble fraction). Subsequent centrifugations
and re-extractions produced RIPA-soluble and SDS-soluble
fractions. The presence of g-synuclein in these fractions was
analysed by SDS–PAGE/western blotting.
Isolation and visualization of g-synuclein filaments
Sarcosyl-insoluble filaments were extracted from mouse spinal
cords as described previously for human neuronal tissues (71).
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Final 100 000g pellets were resuspended in 50 mM Tris–HCl
(pH 7.5) buffer and aliquots were applied onto glow-
discharged carbon-coated 400-mesh copper grids. After block-
ing in 1% BSA/PBS, grids were incubated in 1:50 diluted
affinity purified rabbit anti-mouse g-synuclein SK23 antibody
(31) for 60 min at room temperature followed by goat anti-
rabbit immunoglobulin secondary antibody (Amersham) con-
jugated to 10 nm gold particles. Fibrils were negatively
stained with 1% dodeca-tungstophosphoric acid neutralized
with KOH to pH 6.2 as described previously (72) and observed
at 40 000 or 50 000 magnification under a Philips TEM
208 transmission electron microscope.
Western blotting and antibodies
Proteins separated by SDS–PAGE were transferred to PVDF
membrane using iBlot technology according to manufacturer
(Invitrogen) instructions. Membrane blocking, incubation
with antibodies, washing and chemiluminescent detection
using ECL or ECLþ techniques were carried out as described
previously (31,68). Intensities of bands obtained using AlphaI-
mager 2200 were analysed using AlphaEase 2200 Analysis
Software (AlphaInnotech Corporation). Primary antibodies
against GAPDH (mouse monoclonal, clone 6C5, Santa Cruz
Biotechnology), a-synuclein (mouse monoclonal, clone 42,
BD Transduction Laboratories), b-synuclein (mouse mono-
clonal, clone 8, BD Transduction Laboratories), g-synuclein
(rabbit polyclonal SK23, affinity purified), GFAP (rabbit poly-
clonal, Sigma), Iba1 (mouse monoclonal, clone 1022-5, Santa
Cruz), CD11b (rat monoclonal, clone M1/70.15, Serotec),
NF-L (rabbit monoclonal, clone C28E10, and mouse mono-
clonal, clone DA2, both Cell Signalling), neurofilament H
(rabbit polyclonal, Sigma), heat shock protein B1 (rabbit
monoclonal, Cell Signalling) and heat shock protein 70
(rabbit monoclonal, Cell Signalling) were used.
Immunoprecipitation
Freshly dissected spinal cords from individual animals were
homogenized in 0.5 ml of IP buffer (50 mM Tris–HCl, pH
7.5, 300 mM NaCl, 1.5 mM MgCl2, 1% Triton X-100) with pro-
tease inhibitors (Complete Mini from Roche) and Triton-
soluble fraction was obtained by 10 000g centrifugation
for 10 min at 48C. After presorption on Protein G Sepharose
(Amersham) for 30 min at 48C and removal of beads by cen-
trifugation for 1 min at 1000g, 5 ml of antibody against NF-L
(mouse monoclonal, clone DA2, Cell Signalling) or 20 ml of
antibody against g-synuclein (rabbit polyclonal SK23) were
added, followed by 50 ml of fresh Protein G Sepharose. The
suspension was rotated at 48C for 2 h Sepharose beads were
collected by centrifugation for 1 min at 1000g and washed
four times with IP buffer. Bound proteins were eluted by
boiling beads in 50 ml of SDS–PAGE loading buffer for
10 min.
Histological techniques
Dissected tissues were post-fixed in 4% paraformaldehyde/
PBS or Carnoy’s fixative and embedded in paraffin wax.
Eight micrometre thick sections were cut and immunostained
as described previously (32) using Elite plus kits (Vector lab-
oratories) and 3,30-diaminobenzidine as a substrate. For double
immunofluorescence, secondary Alexa Fluor-conjugated anti-
body (Invitrogen) were used. Images were prepared using
laser scanning confocal microscope Leica TCS SP2 (Leica
Microsystems) and LEICA CONFOCAL 2.00 software. For
detection and counting of amyloid aggregates, spinal cord sec-
tions (four to five animals per age/genotype/condition group)
were stained in 0.5% Congo red solution in 50% ethanol for
7 min followed by a brief differentiation in potassium hydrox-
ide (0.2% in 80% ethanol) and, after several washes in dH2O,
were mounted using Immu-mount (Thermo Electron Corpor-
ation). Fluorescent microscopy was used to analyse the
number of aggregates within a randomly selected 0.1 mm2
area of the spinal cord gray matter. For assessing number of
spinal motor neurons, transverse spinal cord sections were
stained in 0.5% cresyl fast violet (CFV) solution in dH2O
and dissociated in acidified ethanol (0.25% acetic acid in
ethanol). The number of motor neurons (identified by a large
cell body containing Nissl granules, with a clear nuclear envel-
ope containing a strongly stained nucleolus) within the ventral
horn was counted. Results were expressed as per cent of the
average number of motor neurons per ventral horn section in
the wild-type animals.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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